Regnault V, Rivat C, Vallet J P, Francois-Gerard C, Brochier G, Allain J P
Thromb Res. 1987 Jan 1;45(1):51-7. doi: 10.1016/0049-3848(87)90256-8.
A new approach for removing the anti-factor VIII antibodies in hemophilic patients by immunoadsorption is proposed. The method is based on the fact that the anti-factor VIII antibodies were predominantly of the IgG4 subclass; anti-human IgG4 antibodies were covalently linked to agarose and large amounts of anti-factor VIII antibodies can be eliminated. A study of 21 blood samples from hemophilic patients with anti-factor VIII antibodies allows us to confirm the large predominance of IgG4 in the anti-factor VIII population. In some samples, the presence of IgG3 related anti-VIII:C was checked by adsorption on an anti-IgG3 column. In a majority of cases, after IgG4 (or IgG4 + IgG3) immunoadsorption, the substitution therapy becomes possible or easier.
提出了一种通过免疫吸附去除血友病患者体内抗凝血因子VIII抗体的新方法。该方法基于以下事实：抗凝血因子VIII抗体主要为IgG4亚类；抗人IgG4抗体与琼脂糖共价连接，大量抗凝血因子VIII抗体可被清除。对21份来自患有抗凝血因子VIII抗体的血友病患者的血样进行的研究使我们能够确认在抗凝血因子VIII群体中IgG4占主导地位。在一些样本中，通过在抗IgG3柱上吸附来检测与抗VIII:C相关的IgG3的存在。在大多数情况下，经过IgG4（或IgG4 + IgG3）免疫吸附后，替代疗法变得可行或更容易。
